MindWalk (NASDAQ:HYFT) Raised to Hold at Wall Street Zen

Key Points

• Wall Street Zen upgraded MindWalk from “sell” to “hold,” while analyst opinions remain mixed. MarketBeat reports an overall consensus rating of “Hold” and an average price target of $5.00.
• MindWalk shares opened at $1.41, with a 52-week range of $0.99 to $3.25 and a market capitalization of approximately $65.86 million.
• The company reported a quarterly loss of $0.06 per share, missing estimates by $0.01, on revenue of $3.03 million. MindWalk continues to post weak profitability, including a negative net margin of 89.65% and negative return on equity of 92.61%.

MindWalk (NASDAQ:HYFT - Get Free Report) was upgraded by analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a research report issued on Saturday.

HYFT has been the subject of a number of other research reports. HC Wainwright reaffirmed a "buy" rating on shares of MindWalk in a research report on Monday, July 20th. Zacks Research lowered shares of MindWalk from a "hold" rating to a "strong sell" rating in a research report on Tuesday, July 28th. Finally, Weiss Ratings restated a "sell (e+)" rating on shares of MindWalk in a research note on Wednesday, July 15th. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and two have given a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of "Hold" and a consensus target price of $5.00.

MindWalk Price Performance

NASDAQ HYFT opened at $1.41 on Friday. MindWalk has a fifty-two week low of $0.99 and a fifty-two week high of $3.25. The stock's 50-day moving average is $1.46 and its two-hundred day moving average is $1.39. The firm has a market cap of $65.86 million, a P/E ratio of -6.41 and a beta of 0.84. The company has a debt-to-equity ratio of 0.26, a current ratio of 2.80 and a quick ratio of 2.72.

MindWalk (NASDAQ:HYFT - Get Free Report) last released its quarterly earnings results on Wednesday, July 22nd. The company reported ($0.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.01). The company had revenue of $3.03 million for the quarter. MindWalk had a negative return on equity of 92.61% and a negative net margin of 89.65%. On average, analysts anticipate that MindWalk will post -0.21 earnings per share for the current fiscal year.

Hedge Funds Weigh In On MindWalk

A number of institutional investors have recently made changes to their positions in the business. Virtu Financial LLC bought a new stake in MindWalk during the 4th quarter valued at approximately $51,000. GSA Capital Partners LLP acquired a new stake in MindWalk in the 2nd quarter valued at approximately $55,000. Bridgeway Capital Management LLC bought a new position in MindWalk in the 4th quarter worth approximately $91,000. Bank of Montreal Can increased its position in MindWalk by 81.0% in the 4th quarter. Bank of Montreal Can now owns 54,750 shares of the company's stock worth $100,000 after buying an additional 24,500 shares during the period. Finally, XTX Topco Ltd increased its position in MindWalk by 118.6% in the 4th quarter. XTX Topco Ltd now owns 81,721 shares of the company's stock worth $149,000 after buying an additional 44,331 shares during the period. 6.70% of the stock is currently owned by institutional investors.

MindWalk Company Profile

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source